Tg (thyroglobulin) is the only currently available marker which can differentiate approximately 80-90% of papillary thyroid carcinoma (PTC) from thyroid carcinoma. However, Tg is not specific while number of the patients with other thyroid diseases has increased and can not predict the prognosis of carcinoma. It has therefore become necessary to develop a new biomarker of PTC. Our aim is to diagnose PTC correctly, to predict the prognosis of PTC, and to provide tailor-made medical therapy depending on the patient's prognosis developing a new biomarker of PTC and methods for its measurements. This may also enable us to develop a new medical therapy for PTC by suppressing the expression of these biomarkers.
Our aim is to provide tailor-made therapy depending on patient prognosis by developing new biomarkers of PTC and methods for its measurements. We expect that as a result of this study, medical exposure, patient burden and medical expenses can be reduced by eliminating one-size-fits-all medical therapy and unnecessary medical examinations.
